Rajshree Polypack
- Market cap
- ₹ 133 Cr.
- P/E
- 6.5x
- P/B
- 0.7x
- 52-week range
- 14.25 – 26.97
- ROE
- 10%
- ROCE
- 11%
- Dividend yield
- 0%
- Debt / equity
- 0.68
- Sector
- Industrial Products
- Industry
- Packaging
- Listed on
- NSE
About
Rajshree Polypack Limited is an India-based company, which manufactures and trades and sells a range of plastic packaging products. It is primarily involved in manufacturing thermoformed packaging products. The Company is engaged in the business of manufacturing of barrier plastic rigid sheets, semi-rigid sheets for form, fill, and seal (FFS) application and thermoformed primary packaging products and injection molded products for the dairy, food and beverage industries. Its product range includes packaging for the dairy industry, food and beverages (F&B), bakery and confectionaries, trays for sweets and snacks, punnets for fruits and vegetables, electronic packaging, among others. It also developed sealing and lidding laminates for food packaging and undertook product trials with multiple customers. It offers rigid plastic packaging products (along with lids) in various shapes and sizes. The Company operates through its two manufacturing units.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Packaging: 96 companies →Rajshree Polypack against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)6.5 against a typical 18.3: cheaper than most peers (1st = cheapest).11th of 95
- Sales growth+24.7% against a typical +22.9% from a year earlier.35th of 74
- Profit growth+77.9% against a typical +25.3% from a year earlier.17th of 68
- Share price, 3 months−5.4% against a typical −1.8%.51st of 87
- Size₹ 133.1 Cr. market value against a typical ₹ 116.3 Cr. (1st = largest).41st of 88
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Moderate safety, with caution
Rated BBB+ by CRISIL- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil BBB+ | Stable | 10 Aug 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 10 Aug 2026 | Reaffirmed | Crisil BBB+ | — | CRISIL | ₹ 107.48 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 3 Nov 2026Upcoming | Financial Results | To consider and approve the Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026. |
| 5 Aug 2026 | Financial Results | A meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, August 05, 2026, inter alia, to consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter ended June 30, 2026. |
| 29 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 6 Feb 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 13 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
| 13 Aug 2025 | Financial Results/Other business matters | To consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company alongwith Limited Review Report of the Auditors thereon for the quarter ended on June 30, 2025 and other business matters |
| 26 May 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2025 and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 68 | 65 | 69 | 79 | 88 | 73 | 90 | 83 | 86 | 72 | 92 | 103 |
| Expenses | 59 | 56 | 61 | 68 | 76 | 65 | 79 | 72 | 75 | 63 | 77 | 88 |
| Operating Profit | 8 | 9 | 8 | 11 | 12 | 8 | 11 | 10 | 11 | 9 | 14 | 14 |
| OPM % | 12.3% | 13.4% | 11.7% | 13.8% | 13.9% | 10.6% | 11.8% | 12.3% | 12.7% | 12.1% | 15.8% | 14% |
| Other Income | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 2 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 2 | 2 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 4 | 5 | 5 | 5 |
| Profit before tax | 3 | 4 | 3 | 5 | 7 | 2 | 5 | 5 | 6 | 3 | 9 | 9 |
| Tax % | 26.3% | 25.1% | 25.9% | 26.6% | 24.6% | 24.1% | 27.5% | 24.6% | 23.5% | 24.7% | 25.3% | 22.7% |
| Net Profit | 2 | 3 | 2 | 4 | 5 | 2 | 4 | 4 | 5 | 2 | 6 | 7 |
| EPS in Rs | 0.33 | 0.4 | 0.34 | 0.55 | 0.69 | 0.23 | 0.5 | 0.55 | 0.62 | 0.3 | 0.86 | 0.98 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 13%
- 5 Years
- 21%
- 3 Years
- 10%
- TTM
- 6%
- 10 Years
- 8%
- 5 Years
- 14%
- 3 Years
- 17%
- TTM
- 41%
- 10 Years
- —
- 5 Years
- −3%
- 3 Years
- −3%
- TTM
- —
- 10 Years
- 10%
- 5 Years
- 9%
- 3 Years
- 9%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Rajshree Polypack | ₹ 19.72 | ₹ 133 Cr. | 6.5x | 0.7x | 10% | — |
| EPL | ₹ 221.40 | ₹ 7,080 Cr. | 18.4x | 2.7x | — | 7.8% |
| AGI Greenpac | ₹ 686.05 | ₹ 4,441 Cr. | 13.7x | 2x | — | 13.1% |
| Uflex | ₹ 557.20 | ₹ 4,029 Cr. | 13.3x | 0.6x | — | 4.1% |
| TCPL Packaging | ₹ 3,837.55 | ₹ 3,484 Cr. | 38.1x | 5.7x | — | 6.2% |
| Nilkamal | ₹ 1,623.00 | ₹ 2,403 Cr. | 21.3x | 1.7x | — | 3.4% |
Management
- Ramswaroop Radheshyam Thard
- Chairman of the Board, Managing Director, Promoter
- Sunil Sawarmal Sharma
- Chief Financial Officer
- Naresh Radheshyam Thard
- Joint Managing Director, Director, Promoter
- Anand Sajjankumar Rungta
- Additional Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.